PriceTargets.com logo

Treace Medical Concepts - TMCI Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.88
  • Forecasted Upside: 13.22%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$6.96 As of 12/20/2024 06:16 PM ET
▲ +0.06 (0.87%)

This chart shows the closing price for TMCI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Treace Medical Concepts Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMCI

Analyst Price Target is $7.88
▲ +13.22% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Treace Medical Concepts in the last 3 months. The average price target is $7.88, with a high forecast of $8.40 and a low forecast of $7.00. The average price target represents a 13.22% upside from the last price of $6.96.

This chart shows the closing price for TMCI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Treace Medical Concepts. This rating has held steady since April 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Truist FinancialBoost TargetHold ➝ Hold$7.00 ➝ $8.40
12/17/2024JPMorgan Chase & Co.Reiterated RatingNeutral$8.00
11/6/2024Stifel NicolausBoost TargetHold ➝ Hold$7.00 ➝ $8.00
10/14/2024Truist FinancialLower TargetHold ➝ Hold$7.50 ➝ $6.00
8/7/2024UBS GroupBoost TargetNeutral ➝ Neutral$6.50 ➝ $7.00
8/7/2024Truist FinancialLower TargetHold ➝ Hold$9.00 ➝ $7.50
7/16/2024Truist FinancialBoost TargetHold ➝ Hold$7.00 ➝ $9.00
7/15/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$5.50 ➝ $8.00
5/16/2024UBS GroupDowngradeBuy ➝ Neutral$16.00 ➝ $6.50
5/8/2024UBS GroupLower TargetBuy ➝ Buy$17.00 ➝ $16.00
5/8/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $5.50
5/8/2024Truist FinancialDowngradeBuy ➝ Hold$17.00 ➝ $7.00
5/8/2024Stifel NicolausDowngradeBuy ➝ Hold$15.00 ➝ $6.00
5/8/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$15.00 ➝ $8.00
5/8/2024BTIG ResearchDowngradeBuy ➝ Neutral
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$12.00 ➝ $16.00
11/13/2023Morgan StanleyLower TargetOverweight ➝ Overweight$30.00 ➝ $14.00
11/10/2023Truist FinancialLower TargetBuy ➝ Buy$17.00 ➝ $12.00
11/10/2023Stifel NicolausLower TargetBuy ➝ Buy$28.00 ➝ $11.00
10/2/2023Stifel NicolausReiterated RatingBuy ➝ Buy$28.00
9/29/2023UBS GroupInitiated CoverageBuy$24.00
9/12/2023StephensReiterated RatingEqual Weight ➝ Equal Weight$25.00
8/28/2023BTIG ResearchLower TargetBuy ➝ Buy$32.00 ➝ $27.50
8/10/2023StephensLower TargetEqual Weight ➝ Equal Weight$27.00 ➝ $25.00
8/9/2023Truist FinancialLower TargetBuy ➝ Buy$33.00 ➝ $30.00
5/1/2023Truist FinancialInitiated CoverageBuy$33.00
4/17/2023BTIG ResearchBoost TargetBuy$29.00 ➝ $32.00
4/10/2023StephensInitiated CoverageEqual Weight$26.00
3/8/2023Morgan StanleyBoost TargetOverweight$28.00 ➝ $30.00
11/15/2022BTIG ResearchBoost Target$29.00
10/11/2022Morgan StanleyBoost TargetOverweight$23.00 ➝ $28.00
9/21/2022BTIG ResearchBoost TargetBuy$23.00 ➝ $28.00
9/21/2022Stifel NicolausBoost TargetBuy$24.00 ➝ $27.00
8/15/2022BTIG ResearchBoost Target$23.00
8/10/2022Morgan StanleyBoost TargetOverweight$22.00 ➝ $23.00
7/18/2022Stifel NicolausLower Target$32.00 ➝ $21.00
7/15/2022Morgan StanleyLower TargetOverweight$26.00 ➝ $22.00
5/12/2022BTIG ResearchInitiated CoverageBuy$22.00
3/4/2022Morgan StanleyLower TargetOverweight$30.00 ➝ $28.00
3/4/2022Stifel NicolausLower TargetBuy$37.00 ➝ $32.00
1/7/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$30.00
11/5/2021Leerink PartnersLower TargetOutperform$38.00 ➝ $32.00
10/22/2021Leerink PartnersReiterated RatingOutperform
5/26/2021Morgan StanleyBoost TargetEqual Weight$30.00 ➝ $32.00
5/18/2021Leerink PartnersInitiated CoverageOutperform$38.00
5/18/2021JPMorgan Chase & Co.Initiated CoverageOverweight$37.00
5/18/2021Morgan StanleyInitiated CoverageEqual Weight$30.00
5/18/2021Stifel NicolausInitiated CoverageBuy$35.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 11 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 7 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 4 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 3 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Treace Medical Concepts logo
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Read More

Today's Range

Now: $6.96
Low: $6.77
High: $7.11

50 Day Range

MA: $6.94
Low: $4.66
High: $8.78

52 Week Range

Now: $6.96
Low: $3.92
High: $15.98

Volume

319,051 shs

Average Volume

783,198 shs

Market Capitalization

$433.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Treace Medical Concepts?

The following Wall Street research analysts have issued research reports on Treace Medical Concepts in the last twelve months: BTIG Research, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for TMCI.

What is the current price target for Treace Medical Concepts?

0 Wall Street analysts have set twelve-month price targets for Treace Medical Concepts in the last year. Their average twelve-month price target is $7.88, suggesting a possible upside of 13.2%. Truist Financial Co. has the highest price target set, predicting TMCI will reach $8.40 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $7.00 for Treace Medical Concepts in the next year.
View the latest price targets for TMCI.

What is the current consensus analyst rating for Treace Medical Concepts?

Treace Medical Concepts currently has 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TMCI, but not buy more shares or sell existing shares.
View the latest ratings for TMCI.

What other companies compete with Treace Medical Concepts?

Other companies that are similar to Treace Medical Concepts include RxSight, InMode, MiMedx Group, Establishment Labs and BioLife Solutions. Learn More about companies similar to Treace Medical Concepts.

How do I contact Treace Medical Concepts' investor relations team?

Treace Medical Concepts' physical mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The company's listed phone number is 904-373-5940 and its investor relations email address is [email protected]. The official website for Treace Medical Concepts is www.treace.com. Learn More about contacing Treace Medical Concepts investor relations.